Key result
Colchicine is being evaluated in a Cochrane Review protocol to assess its clinical benefits and harms for the primary prevention of cardiovascular outcomes in the general population.
Why the study?
To assess the clinical benefit and harms of colchicine as primary prevention of cardiovascular outcomes in the general population.
Does colchicine prevent cardiovascular outcomes in the general population?
Does colchicine prevent cardiovascular outcomes in the general population?
This is a protocol for a Cochrane Review to assess the efficacy and safety of colchicine for the primary prevention of cardiovascular events.
Answers are grounded in this paper and cite their sources.
Colchicine should not be used for primary CVD prevention pending review; protocol leaves evidence synthesis open for researchers.
This is a protocol for a Cochrane Review (intervention). The objectives are as follows: assess the clinical benefit and harms of colchicine as primary prevention of in the general population.
No takes yet. Share an insight, caveat, or question.
Martí-Carvajal et al. (2022) studied this question. Colchicine is being evaluated in a Cochrane Review protocol to assess its clinical benefits and harms for the primary prevention of cardiovascular outcomes in the general population.
Synapse has enriched 10 related papers. Consider them for comparative context: